Biofidelity to launch Enspyre® technology at AGBT 2025

Enspyre is a next generation sequencing (NGS) preparation technology enabling higher sensitivity variant calling from a fraction of the data

CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2025 /PRNewswire/ -- Biofidelity, a leader in innovative genomic solutions, will present launch details for Enspyre^®, a novel target enrichment technology with a broad spectrum of potential applications that allows for selective enrichment of specified variants prior to sequencing.

"NGS is highly inefficient – with as few as one in 20 million sequenced bases resulting in a variant call. This results in poor signal to noise, severely limiting the potential of NGS that even AI will never unlock," said Biofidelity Co-founder and CEO, Barnaby Balmforth, PhD. "Enspyre removes up to 99% of background DNA prior to sequencing, enabling high throughput NGS applications on benchtop sequencers. This cracks wide open the potential for new applications of NGS across clinical use and research science."

Enspyre (Enrichment by selective pyrophosphorolysis and release) redefines what is possible with NGS by dramatically enhancing signal to noise, enabling the identification of variants with a sequencing depth reduced by more than 95% compared to a non-selective assay. This presents the opportunity to transform a broad spectrum of potential applications within oncology, including minimum residual disease (MRD) testing, and beyond. Additional benefits include lower data processing time and significantly decreased data storage requirements. Cumulatively, these benefits could significantly improve sensitivity, bring down the cost of sequencing necessary for MRD detection, and deliver results significantly faster for patients.

Biofidelity will present Enspyre proof of concept data at the Advances in Genome Biology and Technology (AGBT) General Meeting in Marco Island, Florida, February 23-26.

The poster (#434) entitled: Enspyre: A novel enrichment technology for selected DNA variants using pyrophosphorolysis will be presented on Tuesday, February 25, 2025 from 4:45-6:10pm EST.

Enspyre technology is complementary to Biofidelity's PCR-based Aspyre^® technology and the commercially available Aspyre^® Lung product which enables fast, simple, decentralized testing for non-small cell lung cancer biomarkers in tissue and blood. Together, these two technologies enable a pipeline of products to be purpose-built to meet critical unmet needs throughout oncology. 

Biofidelity is taking an 'Intel Inside' approach to making Enspyre commercially available. The company is actively pursuing partnering and licensing opportunities with multiple global pharmaceutical companies, contract research organizations (CROs) and precision medicine drug developers.

To learn more about Enspyre, please visit biofidelity.com/products/enspyre

About Biofidelity
Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to improving and extending the lives of patients with cancer by enabling better targeting of therapies, early detection of treatment resistance and routine monitoring of treatment response. Visit biofidelity.com and connect with us on LinkedIn.

Contact
Andrea Conners
+1 239-728-1202
[email protected]

SOURCE Biofidelity